CLINICAL IMPLICATIONS OF VARIABLE ANTIARRHYTHMIC DRUG-METABOLISM

被引：32

作者：

BUCHERT, E

WOOSLEY, RL

机构：

[1] Department of Pharmacology, Georgetown University Medical Center, Washington, DC, 20007-2195, 3900 Reservoir Road, NW

来源：

PHARMACOGENETICS | 1992年 / 2卷 / 01期

关键词：

D O I：

10.1097/00008571-199202000-00002

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Due to their narrow therapeutic indices, antiarrhythmic drugs have a great potential for adverse outcome. This is amplified by extreme inter-individual variability in their disposition and their pharmacological actions. Genetically determined inter-individual differences in metabolism account for a great deal of this variability. However, because of active metabolites, chirally-specific actions and chirally-specific metabolism, it is not possible to generalize about the outcome of phenotypic differences in the metabolism of a given drug. Careful study of these factors can enable physicians to understand the spectrum of potential responses to a drug. Newly developed molecular biology techniques now make it possible to determine the genotype for the CYP2D6 gene that controls metabolism of many antiarrhythmic drugs. This information, combined with a full understanding of the drugs' clinical pharmacology now makes it possible to predict the clinical outcome for drugs such as encainide, flecainide, mexiletine, propafenone and combinations of these drugs with quinidine.

引用

页码：2 / 11

页数：10

共 62 条

[11] Dawson A.K., Roden D.M., Duff H.J., Woosley R.L., Smith R.F., Differential effects of O-demethyl encainide on induced and spontaneous arrhythmias in the conscious dog, Am J Cardiol, 54, pp. 654-658, (1984)
[12] Duff H.J., Roden D.M., Carey E.L., Wang T., Primm R.K., Woosley R.L., Spectrum of antiarrhythmic response to encainide, Am J Cardiol, 56, pp. 887-891, (1985)
[13] Duff H.J., Roden D.M., Maffucci R.J., Vesper B.S., Conard G.J., Higgins S.B., Oates J.A., Smith R.F., Woosley R.L., Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide, Am J Cardiol, 48, pp. 1133-1141, (1981)
[14] Eichelbaum M., Bavr M.P., Dengler H.J., Osikowska-Evers B.O., Tieves G., Zekorn C., Rittner C., Chromosome assignment of human cytochrome P-450 (Debrisoquine/sparteine type) to chromosome 22, Br J Clin Pharm, 23, pp. 455-458, (1987)
[15] Funck-Brentano C., Jacqz-Aigrain E., Roux A., Poirier J.M., Jaillon P., Influence of amiodarone on genetically determined drug metabolism in humans, Clin Pharmacol Ther, 50, pp. 259-266, (1991)
[16] Funck-Brentano C., Jared L.L., Roden D.M., Woosley R.L., Interaction of procainamide and N-acetylprocainamide in man, Circulation, 76, (1987)
[17] Funck-Brentano C., Kroemer H.K., Pavlou H., Woosley R.L., Roden D.M., Genetically-determined interaction between propafenone and low dose quinidine: Role of active metabolites in modulating net drug effect, Br J Clin Pharmacol, 27, pp. 435-444, (1989)
[18] Funck-Brentano C., Light R.T., Lineberry M.D., Wright G.M., Roden D.M., Woosley R.L., Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans, J Cardiovasc Pharmacol, 14, pp. 364-373, (1989)
[19] Funck-Brentano C., Turgeon J., Woosley R.L., Roden D.M., Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics: Influence of genetic polymorphism, J Pharmacol Exp Ther, 249, pp. 134-142, (1989)
[20] Gaedigk A., Blum M., Gaedigk R., Eichelbaum M., Meyer U.A., Deletion of the entire cytochrome P-450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism, Amer J Hum Genet, 48, pp. 943-950, (1991)

← 1 2 3 4 5 6 7 →